Targeting p70S6K would restrict the blockage of PI3K-AKT-mTOR axis to its effect on liver fibrosis without interfering with the actions of the upstream members of this signaling pathway, hereby representing a potentially safer and more tolerable therapeutic strategy. This evidence concerns the gene AKT1 and Hepatic fibrosis.